Teladoc Health (TDOC) Cash & Equivalents (2014 - 2026)

Teladoc Health (TDOC) has 13 years of Cash & Equivalents data on file, last reported at $750.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 37.09% year-over-year to $750.7 million; the trailing twelve-month figure through Mar 2026 stood at $750.7 million (down 37.09% YoY), and the FY2025 full-year result was $781.1 million, down 39.84% from the prior year.
• Cash & Equivalents declined to $750.7 million in Q1 2026, from $781.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q4 2024 to a low of $679.6 million in Q2 2025.
• A 5-year average of $968.8 million and a median of $918.2 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents advanced 23.56% in 2024 and slumped 41.61% in 2025, its largest moves.
• Tracing TDOC's Cash & Equivalents over 5 years: stood at $918.2 million in 2022, then grew by 22.38% to $1.1 billion in 2023, then gained by 15.54% to $1.3 billion in 2024, then sank by 39.84% to $781.1 million in 2025, then dropped by 3.89% to $750.7 million in 2026.
• Business Quant data shows TDOC's Cash & Equivalents at $750.7 million in Q1 2026, $781.1 million in Q4 2025, and $726.2 million in Q3 2025.